Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05155046
Other study ID # 10000481
Secondary ID 000481-C
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 31, 2022
Est. completion date September 30, 2025

Study information

Verified date June 3, 2024
Source National Institutes of Health Clinical Center (CC)
Contact Debbie Nathan, R.N.
Phone (301) 451-8968
Email dnathan@mail.nih.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility: People ages 18 and older with newly diagnosed prostate cancer who have no evidence of distant metastatic disease and plan to get stereotactic body radiation therapy (SBRT) with or without androgen deprivation therapy (ADT). Design: Participants will be screened with: Medical history Physical exam Blood tests MRI Participants will have baseline MRI and PET/CT scans. For the MRI, they may get a contrast agent by IV injection. For the PET/CT scan, they will get an IV injection of 18FDCFPyL. About 1 to 2 hours later, they will get the PET/CT scan. During the scans, participants will lie on their back and remain still for 45 minutes to 1 hour. These scans will be repeated at different points during the study. Participants will get SBRT with or without ADT. Participants will complete questionnaires about their quality of life. Participants will be asked about any symptoms they are having. They will also be asked about medications they are using. They may have a physical exam. Participants will give blood and urine samples. They will give a tumor sample from a biopsy they have had in the past. After treatment, participants will have follow-up visits. These will occur 1 month after treatment, then every 3 months for a year, and then every 6 months for 1 more year.


Description:

Background: Radiotherapy is a highly effective treatment for localized prostate cancer; however, recurrence is more common in patients with unfavorable intermediate and high-risk prostate cancer, and is usually diagnosed by rising prostate specific antigen (PSA - biochemical failure). Early identification of disease persistence or recurrence before meeting criteria of biochemical failure may allow effective potentially curative salvage treatment, but identification of local recurrence or persistence at early stages is challenging. CT imaging is relatively insensitive at localizing recurrence, while MRI is more sensitive for local recurrence but is non-specific. Prostate specific membrane antigen (PSMA) targeted PET imaging was recently FDA approved for imaging men with suspected prostate cancer metastases who are potentially curable by radiation or surgery. PSMA based imaging has been used in prospective trials to define extent of disease and to alter radiation treatment volumes. 18F-DCFPyL, a second generation PSMA PET agent that binds with high affinity to PSMA yet clears rapidly from the blood pool, has recently been approved by the FDA as a method to stage high risk cancer and detect recurrent disease. Primary Objective: To define 18F-DCFPyL PET/CT imaging response in participants with localized prostate cancer after treatment with stereotactic body radiation therapy (SBRT) with or without androgen deprivation therapy (ADT). Eligibility: Biopsy proven localized prostate cancer in whom prostate SBRT with or without ADT is appropriate therapy Must have at least 1 MRI detected, biopsy proven site of prostate cancer. ECOG 0-2 Design: This is a single center, prospective study aimed at recruiting the following cohorts: Up to 40 evaluable participants with presumed localized prostate cancer (intermediate or high risk) scheduled to undergo radiotherapy with systemic androgen deprivation therapy. Up to 40 evaluable participants with presumed localized prostate cancer (intermediate or high risk) scheduled to undergo SBRT without androgen deprivation therapy. Up to 20 evaluable participants with presumed localized prostate cancer (intermediate or high risk) scheduled to undergo radiotherapy with localized androgen deprivation therapy. To account for non-evaluable participants, such as those found to have regional or distant metastases on pretreatment 18F-DCFPyL, the accrual ceiling will be set at 120. Participants receiving neoadjuvant androgen deprivation therapy will undergo a second 18F-DCFPyL PET/CT and multiparametric MRI (mpMRI) at 8 weeks after initiation of ADT but before SBRT. All participants will undergo 18F-DCFPyL PET/CT and mpMRI 6 months following completion of SBRT and at recurrence, if applicable. Participants will be followed for up to 2 years after completion of SBRT to evaluate longitudinal quality of life and biochemical control.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date September 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility - INCLUSION CRITERIA: - Biopsy proven localized prostate cancer in whom stereotactic body radiation treatment (SBRT) with or without neoadjuvant androgen deprivation therapy (ADT) is planned for definitive management (NIH laboratory of pathology confirmation is not required). - Must have at least 1 MRI detected, biopsy proven localized prostate cancer. - Age >= 18 years - ECOG performance status <= 2 - For individuals with evidence of human immunodeficiency virus (HIV) infection, individuals must be on effective anti-retroviral therapy with undetectable viral load within the prior 6 months are eligible. - For individuals with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. - For individuals with a history of hepatitis C virus (HCV), the infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. - Ability of subject to understand and the willingness to sign a written informed consent document. - Men must agree to use adequate contraception with their partner (hormonal or barrier method of birth control; abstinence) for the duration of study participation and 2 months after the last 18F-DCFPyL scan. EXCLUSION CRITERIA: - Receiving prior androgen deprivation therapy, radiotherapy, or surgery for prostate cancer. - Any condition that is likely to interfere with study procedures or results. - Individuals in whom pelvic nodal irradiation is planned. - Serum creatinine > 2 times the upper limit of normal. - Weighing > 350 lbs (weight limit for scanner table), or unable to fit in imaging gantry. - Evidence of tumor spread beyond the prostate/seminal vesicles (lymph nodes, metastases). - Contraindications to radiation or SBRT.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18F-DCFPyL
18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Imaging response to treatment For the purpose of this study, the imaging response to treatment will be categorized separately in the radiation treatment volume (in field; local) and distantly (outside the radiation treatment volume). In-field (in the radiation target volume) 18F-DCFPyL PET/CT treatment response in field will be evaluated using a descriptor (complete, partial, progression) based on maximum SUV and volume of uptake relative to the pre-treatment imaging. Presence of new areas of uptake suspicious for prostate cancer outside of the region of radiation treatment will be considered progression but will be scored separately and will not impact the assessment of response from radiation locally. Baseline, 8 weeks after ADT initiation (if applicable), 6 months post SBRT, at recurrence
See also
  Status Clinical Trial Phase
Completed NCT03996005 - MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer N/A
Withdrawn NCT02159690 - A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Phase 2
Completed NCT00196781 - Treatment Decision Making in Early-Stage Prostate Cancer Phase 3
Recruiting NCT03821246 - Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Phase 2
Active, not recruiting NCT03814252 - Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer N/A
Completed NCT01931046 - Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer Phase 1/Phase 2
Completed NCT01714219 - Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy N/A
Active, not recruiting NCT03315754 - Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. Phase 2
Recruiting NCT05010343 - Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer Phase 2
Recruiting NCT06325995 - Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer N/A
Recruiting NCT06051942 - PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs N/A
Completed NCT02297386 - [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer Phase 1
Not yet recruiting NCT06117059 - The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance N/A
Withdrawn NCT04225299 - Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer Phase 3
Recruiting NCT06054867 - PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System N/A
Active, not recruiting NCT02435472 - Active Surveillance Exercise Clinical Trial N/A
Completed NCT00717613 - Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting N/A
Completed NCT02662673 - Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device N/A
Completed NCT01902680 - Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant. Phase 2
Recruiting NCT00651417 - Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue Phase 2